Avelumab reduces STAT3 expression with effects on IL-17RA and CD15
Our study suggests that the targeting of PD-L1 with avelumab alters the expression of CD15 and IL-17RA, which play an important prognostic and therapeutic role in novel anticancer therapy.
Authors
- Julita Kulbacka (ORCID: https://orcid.org/0000-0001-8272-5440)
- Bartosz Małkiewicz (ORCID: https://orcid.org/0000-0002-5933-3753)
- Agnieszka Szewczyk
- Natalia Sauer (ORCID: https://orcid.org/0000-0002-1898-3952)
- Tomasz Szydełko (ORCID: https://orcid.org/0000-0002-1360-0422)
- J Karwacki
- Jolanta Saczko (ORCID: https://orcid.org/0000-0001-5273-5293)
- Wojciech Szlasa (ORCID: https://orcid.org/0000-0002-5477-5771)
Institutions
- Wroclaw Medical University (PL)
Publication Details
- Journal
- Dental and Medical Problems
- Published
- 2024-10-31
- DOI
- https://doi.org/10.17219/dmp/176374
- Citations
- 1
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.28